Biocon Ltd reported a strong set of numbers in the fourth quarter of FY25, with net profit after exceptional items surging 154% to ₹344.5 crore, compared to ₹135.5 crore a year earlier. On a like-for-like basis, net profit rose 162%. The figure was also well above CNBC-TV18’s poll estimate of ₹167.7 crore.
Revenue grew 12.8% year-on-year (YoY) to ₹4,417 crore, beating expectations of ₹4,168.6 crore.
Operating performance remained strong, with EBITDA rising 17.7% YoY to ₹1,078.2 crore versus ₹915.9 crore in the same quarter last year. This was ahead of the projected ₹943.3 crore.
The EBITDA margin expanded to 24.4% from 23.4% a year ago, higher than the estimated 22.6%.
The company’s board has recommended a final dividend of ₹0.50 per equity share (10% of the face value of ₹5), subject to shareholder approval. The record date is July 4, 2025, and the dividend will be paid on or before September 5, 2025.
Ahead of the earnings release, shares of Biocon closed 3.46% lower at ₹334.60 on the BSE.
